Myocardial recovery with left ventricular assist devices

Current Treatment Options in Cardiovascular Medicine

Volumn 14, Issue 4, 2012, Pages 370-383

  Guglin, Maya ^a   Miller, Leslie ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Heart failure; Ventricular assist device; Ventricular recovery

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CARVEDILOL; CLENBUTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; SPIRONOLACTONE;

AGE DISTRIBUTION; AORTA VALVE REPLACEMENT; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL EVALUATION; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DEVICE REMOVAL; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG MEGADOSE; ECHOCARDIOGRAPHY; EXERCISE; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEMODYNAMICS; HUMAN; KIDNEY TRANSPLANTATION; LEFT VENTRICULAR ASSIST DEVICE; LONG TERM CARE; MUSCLE ATROPHY; MUSCLE HYPERTROPHY; MUSCLE REGENERATION; NONHUMAN; NONISCHEMIC CARDIOMYOPATHY; PATIENT MONITORING; PROTEIN EXPRESSION; REST; REVIEW; SHORT COURSE THERAPY; SYMPTOMATOLOGY; TREATMENT RESPONSE; WEANING;

EID: 84865677146     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0190-9     Document Type: Review

References (92)

1. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA: The journal of the American Medical Association. 2011;306:1669-78.
2. Verma A, Wulffhart Z, Lakkireddy D, et al. Incidence of left ventricular function improvement after primary prevention ICD implantation for non-ischaemic dilated cardiomyopathy: A multicentre experience. Heart (British Cardiac Society). 2010;96:510-5.
3. Antonio N, Teixeira R, Coelho L, et al. Identification of 'super-responders' to cardiac resynchronization therapy: The importance of symptom duration and left ventricular geometry. Europace: European pacing, arrhythmias, and cardiac electrophysiology: Journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2009;11:343-9.
4. Reant P, Zaroui A, Donal E, et al. Identification and characterization of super-responders after cardiac resynchronization therapy. Am J Cardiol. 2010;105:1327-35.
5. Rickard J, Kumbhani DJ, Popovic Z, et al. Characterization of super-response to cardiac resynchronization therapy. Heart rhythm: The official journal of the Heart Rhythm Society. 2010;7:885-9.
6. Serdoz LV, Daleffe E, Merlo M, et al. Predictors for restoration of normal left ventricular function in response to cardiac resynchronization therapy measured at time of implantation. Am J Cardiol. 2011;108:75-80.
7. Ypenburg C, van Bommel RJ, Borleffs CJ, et al. Longterm prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up. J Am Coll Cardiol. 2009;53:483-90.
8. Connolly HM, Oh JK, Orszulak TA, et al. Aortic valve replacement for aortic stenosis with severe left ventricular dysfunction. Prognostic indicators. Circulation. 1997;95:2395-400. (Pubitemid 27224734)
9. Morris JJ, Schaff HV, Mullany CJ, et al. Determinants of survival and recovery of left ventricular function after aortic valve replacement. Ann Thorac Surg. 1993;56:22-9. discussion 29-30.
10. Pilgrim T, Wenaweser P, Meuli F, et al. Clinical outcome of high-risk patients with severe aortic stenosis and reduced left ventricular ejection fraction undergoing medical treatment or TAVI. PLoS One. 2011;6: E27556.
11. Bouchart F, Tabley A, Litzler PY, Haas-Hubscher C, Bessou JP, Soyer R. Myocardial revascularization in patients with severe ischemic left ventricular dysfunction. Long term follow-up in 141 patients. European journal of cardio-thoracic surgery: Official journal of the European Association for Cardio-thoracic Surgery. 2001;20:1157-62. (Pubitemid 33054073)
12. Elefteriades JA, Tolis Jr G, Levi E, Mills LK, Zaret BL. Coronary artery bypass grafting in severe left ventricular dysfunction: Excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol. 1993;22:1411-7. (Pubitemid 23316367)
13. Wali RK, Wang GS, Gottlieb SS, et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with endstage renal disease. J Am Coll Cardiol. 2005;45:1051-60. (Pubitemid 40432438)
14. Patel MR, Smalling RW, Thiele H, Barnhart HX, Zhou Y, Chandra P, Chew D, Cohen M, French J, Perera D, Ohman EM. Intra-aortic BalloonCounterpulsation and Infarct Size in Patients With Acute Anterior Myocardial Infarction Without Shock: TheCRISPAMI Randomized Trial. JAMA. 2011;306(12):1329-37.
15. Engstrom AE, Sjauw KD, Baan J, et al. Long-term safety and sustained left ventricular recovery: Longterm results of percutaneous left ventricular support with Impella LP2.5 in ST-elevation myocardial infarction. EuroIntervention: Journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2011;6:860-5.
16. Hsu KH, Chi NH, Yu HY, et al. Extracorporeal membranous oxygenation support for acute fulminant myocarditis: Analysis of a single center's experience. European journal of cardio-thoracic surgery: Official journal of the European Association for Cardio-thoracic Surgery. 2011;40:682-8.
17. Asaumi Y, Yasuda S, Morii I, et al. Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation. Eur Hear J. 2005;26:2185-92. (Pubitemid 41408005)
18. Ishida K, Wada H, Sakakura K et al. Long-term follow-up on cardiac function following fulminant myocarditis requiring percutaneous extracorporeal cardiopulmonary support. Heart and vessels 2011.
19. Grundeman PF, Tukkie R, Moulijn AC, et al. Shortterm biventricular circulatory support in the regionally stunned pig myocardium. Thorac Cardiovasc Surg. 1993;41:290-6. (Pubitemid 23338899)
20. Colombo T, Garatti A, Bruschi G, et al. First successful bridge to recovery with the Impella Recover 100 left ventricular assist device for fulminant acute myocarditis. Italian heart journal: Official journal of the Italian Federation of Cardiology. 2003;4:642-5.
21. Khalife WI, Kar B. The TandemHeart pVAD in the treatment of acute fulminant myocarditis. Texas Heart Institute journal/from the Texas Heart Institute of St Luke's Episcopal Hospital, Texas Children's Hospital. 2007;34:209-13.
22. Chandra D, Kar B, Idelchik G, et al. Usefulness of percutaneous left ventricular assist device as a bridge to recovery from myocarditis. Am J Cardiol. 2007;99:1755-6. (Pubitemid 46874330)
23. Rajagopal V, Steahr G, Wilmer CI, Raval NY. A novel percutaneous mechanical biventricular bridge to recovery in severe cardiac allograft rejection. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2010;29:93-5.
24. Santise G, Petrou M, Pepper JR, Dreyfus G, Khaghani A, Birks EJ. Levitronix as a short-term salvage treatment for primary graft failure after heart transplantation. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2006;25:495-8.
25. Clough RE, Vallely MP, Henein MY, Pepper Jr. Levitronix ventricular assist device as a bridge-to-recovery for post-cardiotomy cardiogenic shock. Int J Cardiol. 2009;134:408-9.
26. Lauten A, Strauch JT, Groetzner J, Wahlers T. Myocardial failure caused by traumatic dissection of left coronary system-ventricular recovery with temporary circulatory support. J Card Surg. 2007;22:238-9. (Pubitemid 46683957)
27. Emmert MY, Pretre R, Ruschitzka F, Krahenmann F, Falk V, Wilhelm MJ. Peripartum cardiomyopathy with cardiogenic shock: Recovery after prolactin inhibition and mechanical support. Ann Thorac Surg. 2011;91:274-6.
28. Lund LH, Grinnemo KH, Svenarud P, van der Linden J, Eriksson MJ. Myocardial recovery in peri-partum cardiomyopathy after continuous flow left ventricular assist device. J Cardiothorac Surg. 2011;6:150.
29. John R, Long JW, Massey HT, et al. Outcomes of a multicenter trial of the Levitronix CentriMag ventricular assist system for short-term circulatory support. J Thorac Cardiovasc Surg. 2011;141:932-9.
30. Morgan JA, Stewart AS, Lee BJ, Oz MC, Naka Y. Role of the Abiomed BVS 5000 device for short-term support and bridge to transplantation. ASAIO journal (American Society for Artificial Internal Organs: 1992). 2004;50:360-3. (Pubitemid 38917884)
31. Nakatani S, McCarthy PM, Kottke-Marchant K, et al. Left ventricular echocardiographic and histologic changes: Impact of chronic unloading by an implantable ventricular assist device. J Am Coll Cardiol. 1996;27:894-901.
32. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation. 1998;97:2316-22. (Pubitemid 28280385)
33. Frazier OH, Benedict CR, Radovancevic B, et al. Improved left ventricular function after chronic left ventricular unloading. Ann Thorac Surg. 1996;62:675-81. discussion 681-2.
34. Etz CD, Welp HA, Tjan TD, et al. Medically refractory pulmonary hypertension: Treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg. 2007;83:1697-705. (Pubitemid 46616800)
35. John R, Liao K, Kamdar F, Eckman P, Boyle A, Colvin-Adams M. Effects on pre-and posttransplant pulmonary hemodynamics in patients with continuous-flow left ventricular assist devices. J Thorac Cardiovasc Surg. 2010;140:447-52. This article describes beneficial changes of LVAD on hemodynamics, especially on pulmonary circulation.
36. Santamore WP, Gray Jr LA. Left ventricular contributions to right ventricular systolic function during LVAD support. Ann Thorac Surg. 1996;61:350-6. (Pubitemid 26053537)
37. Ziv O, Dizon J, Thosani A, Naka Y, Magnano AR, Garan H. Effects of left ventricular assist device therapy on ventricular arrhythmias. J Am Coll Cardiol. 2005;45:1428-34. (Pubitemid 40615614)
38. Refaat MM, Tanaka T, Kormos RL, et al. Survival benefit of implantable cardioverter-defibrillators in left ventricular assist device-supported heart failure patients. J Card Fail. 2012;18:140-5. This article demonstrates that in spite of being relatively well tolerated, ventricular tachycardia increases mortality in LVAD patients, and AICDs carry survival benefit.
39. Kuhn M, Voss M, Mitko D, et al. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure. Cardiovasc Res. 2004;64:308-14. (Pubitemid 39361692)
40. James KB, McCarthy PM, Thomas JD, et al. Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. Circulation. 1995;92:II191-5.
41. Torre-Amione G, Stetson SJ, Youker KA, et al. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: A potential mechanism for cardiac recovery. Circulation. 1999;100:1189-93. (Pubitemid 29426594)
42. Butler J, Geisberg C, Howser R, et al. Relationship between renal function and left ventricular assist device use. Ann Thorac Surg. 2006;81:1745-51. (Pubitemid 350030010)
43. Friedel N, Viazis P, Schiessler A, et al. Recovery of end-organ failure during mechanical circulatory support. European journal of cardio-thoracic surgery: Official journal of the European Association for Cardio-thoracic Surgery. 1992;6:519-22. discussion 523.
44. Ogletree-Hughes ML, Stull LB, Sweet WE, Smedira NG, McCarthy PM, Moravec CS. Mechanical unloading restores beta-adrenergic responsiveness and reverses receptor downregulation in the failing human heart. Circulation. 2001;104:881-6. (Pubitemid 32778037)
45. Takeishi Y, Jalili T, Hoit BD, et al. Alterations in Ca2+ cycling proteins and G alpha q signaling after left ventricular assist device support in failing human hearts. Cardiovasc Res. 2000;45:883-8. (Pubitemid 30089650)
46. Drakos SG, Kfoury AG, Selzman CH, et al. Left ventricular assist device unloading effects on myocardial structure and function: Current status of the field and call for action. Curr Opin Cardiol. 2011;26:245-55.
47. Klotz S, Deng MC, Stypmann J, et al. Left ventricular pressure and volume unloading during pulsatile versus nonpulsatile left ventricular assist device support. Ann Thorac Surg. 2004;77:143-9. discussion 149-50. (Pubitemid 38130000)
48. Haft J, Armstrong W, Dyke DB, et al. Hemodynamic and exercise performance with pulsatile and continuous-flow left ventricular assist devices. Circulation. 2007;116:I8-I15. (Pubitemid 47480764)
49. Welp H, Rukosujew A, Tjan TD, et al. Effect of pulsatile and non-pulsatile left ventricular assist devices on the renin-angiotensin system in patients with end-stage heart failure. Thorac Cardiovasc Surg. 2010;58 Suppl 2:S185-8.
50. Klotz S, Foronjy RF, Dickstein ML, et al. Mechanical unloading during left ventricular assist device support increases left ventricular collagen crosslinking and myocardial stiffness. Circulation. 2005;112:364-74. (Pubitemid 41022077)
51. Thompson EW, Marino TA, Uboh CE, Kent RL, Cooper Gt. Atrophy reversal and cardiocyte redifferentiation in reloaded cat myocardium. Circ Res. ;54:367-77.
52. Oriyanhan W, Tsuneyoshi H, Nishina T, Matsuoka S, Ikeda T, Komeda M. Determination of optimal duration of mechanical unloading for failing hearts to achieve bridge to recovery in a rat heterotopic heart transplantation model. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2007;26:16-23. (Pubitemid 46096745)
53. Levine S, Nguyen T, Taylor N, et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med. 2008;358:1327-35. (Pubitemid 351468409)
54. Milting H, ELB A, Kassner A, et al. The time course of natriuretic hormones as plasma markers of myocardial recovery in heart transplant candidates during ventricular assist device support reveals differences among device types. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2001;20:949-55. (Pubitemid 32824140)
55. Xydas S, Rosen RS, Ng C, et al. Mechanical unloading leads to echocardiographic, electrocardiographic, neurohormonal, and histologic recovery. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2006;25:7-15. (Pubitemid 43049658)
56. Maybaum S, Mancini D, Xydas S, et al. Cardiac improvement during mechanical circulatory support: A prospective multicenter study of the LVAD Working Group. Circulation. 2007;115:2497-505. (Pubitemid 46763223)
57. Maybaum S, Epstein S, Beniaminovitz A, et al. Partial loading of the left ventricle during mechanical assist device support is associated with improved myocardial function, blood flow and metabolism and increased exercise capacity. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2002;21:446-54. (Pubitemid 34240465)
58. Frazier OH, Myers TJ. Left ventricular assist system as a bridge to myocardial recovery. Ann Thorac Surg. 1999;68:734-41. (Pubitemid 29527024)
59. Farrar DJ, Holman WR, McBride LR, et al. Long-term follow-up of Thoratec ventricular assist device bridgeto-recovery patients successfully removed from support after recovery of ventricular function. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2002;21:516-21.
60. Matsumiya G, Monta O, Fukushima N, et al. Who would be a candidate for bridge to recovery during prolonged mechanical left ventricular support in idiopathic dilated cardiomyopathy? J Thorac Cardiovasc Surg. 2005;130:699-704. (Pubitemid 41265707)
61. Dandel M, Weng Y, Siniawski H, et al. Prediction of cardiac stability after weaning from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy. Circulation. 2008;118: S94-S105.
62. Petrou M, Wynne DG, Boheler KR, Yacoub MH. Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes. Circulation. 1995;92: II483-9.
63. Maltin CA, Hay SM, Delday MI, Reeds PJ, Palmer RM. Evidence that the hypertrophic action of clenbuterol on denervated rat muscle is not propranololsensitive. Br J Pharmacol. 1989;96:817-22. (Pubitemid 19100036)
64. Maltin CA, Hay SM, Delday MI, Smith FG, Lobley GE, Reeds PJ. Clenbuterol, a beta agonist, induces growth in innervated and denervated rat soleus muscle via apparently different mechanisms. Bioscience reports. 1987;7:525-32. (Pubitemid 18074690)
65. Maltin CA, Hay SM, McMillan DN, Delday MI. Tissue specific responses to clenbuterol; temporal changes in protein metabolism of striated muscle and visceral tissues from rats. Growth regulation. 1992;2:161-6.
66. Maltin CA, Delday MI, Watson JS, et al. Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clinical science (London, England: 1979). 1993;84:651-4. (Pubitemid 23171175)
67. Liggett SB, Tepe NM, Lorenz JN, et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: Critical role for expression level. Circulation. 2000;101:1707-14. (Pubitemid 30196632)
68. Tevaearai HT, Eckhart AD, Walton GB, Keys JR, Wilson K, Koch WJ. Myocardial gene transfer and overexpression of beta2-adrenergic receptors potentiates the functional recovery of unloaded failing hearts. Circulation. 2002;106:124-9. (Pubitemid 34747452)
69. Soppa GK, Smolenski RT, Latif N, et al. Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle. Am J Physiol Heart Circ Physiol. 2005;288:H1468-76. (Pubitemid 40270059)
70. Terracciano CM, Hardy J, Birks EJ, Khaghani A, Banner NR, Yacoub MH. Clinical recovery from endstage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy. Circulation. 2004;109:2263-5. (Pubitemid 38656863)
71. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006;355:1873-84. (Pubitemid 44664645)
72. Birks EJ, George RS, Hedger M, et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: A prospective study. Circulation. 2011;123:381-90. This is an interesting study replicating the clenbuterol protocol with continuous-flow devices.
73. Kamalakkannan G, Petrilli CM, George I, et al. Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2008;27:457-61. (Pubitemid 351418249)
74. George I, Xydas S, Mancini DM, et al. Effect of clenbuterol on cardiac and skeletal muscle function during left ventricular assist device support. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2006;25:1084-90. (Pubitemid 44311534)
75. Klotz S, Burkhoff D, Garrelds IM, Boomsma F, Danser AH. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: Therapeutic consequences? Eur Hear J. 2009;30:805-12.
76. Klotz S, Danser AH, Foronjy RF, et al. The impact of angiotensin- converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol. 2007;49:1166-74. (Pubitemid 46400328)
77. Klotz S, Jan Danser AH, Burkhoff D. Impact of left ventricular assist device (LVAD) support on the cardiac reverse remodeling process. Prog Biophys Mol Biol. 2008;97:479-96.
78. Dandel M, Weng Y, Siniawski H, et al. Heart failure reversal by ventricular unloading in patients with chronic cardiomyopathy: Criteria for weaning from ventricular assist devices. Eur Hear J. 2011;32:1148-60. This is an outstanding study summarizing predictors of recovery and describing a step-by-step logistic of weaning from LVAD.
79. Segura AM, Frazier OH, Demirozu Z, Buja LM. Histopathologic correlates of myocardial improvement in patients supported by a left ventricular assist device. Cardiovascular pathology: The official journal of the Society for Cardiovascular Pathology. 2011;20:139-45.
80. Hall JL, Birks EJ, Grindle S, et al. Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy. Eur Hear J. 2007;28:613-27. (Pubitemid 47355497)
81. Khan T, Delgado RM, Radovancevic B, et al. Dobutamine stress echocardiography predicts myocardial improvement in patients supported by left ventricular assist devices (LVADs): Hemodynamic and histologic evidence of improvement before LVAD explantation. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2003;22:137-46. (Pubitemid 36173670)
82. Khan T, Okerberg K, Hernandez A, et al. Assessment of myocardial recovery using dobutamine stress echocardiography in LVAD patients. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2001;20:202-3.
83. Cotter G, Moshkovitz Y, Kaluski E, et al. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Hear Fail. 2003;5:443-51. (Pubitemid 37021638)
84. Jakovljevic DG, George RS, Nunan D, et al. The impact of acute reduction of continuous-flow left ventricular assist device support on cardiac and exercise performance. Heart (British Cardiac Society). 2010;96:1390-5.
85. George RS, Sabharwal NK, Webb C, et al. Echocardiographic assessment of flow across continuousflow ventricular assist devices at low speeds. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2010;29:1245-52.
86. Potapov EV, Schweiger M, Krabatsch T. Percutaneous balloon occlusion of a left ventricular assist device outflow cannula to facilitate evaluation of myocardial recovery. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2011;30:1300-1.
87. Formica P, Murthy S, Edwards P, Goldstein D, Maybaum S. A structured 3-step approach to evaluate cardiac recovery with continuous flow circulatory support. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2010;29:1440-2. This letter describes a detailed protocol of monitoring for recovery and weaning of LVADs.
88. Mancini DM, Beniaminovitz A, Levin H, et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation. 1998;98:2383-9. (Pubitemid 28549781)
89. Gorcsan 3rd J, Severyn D, Murali S, Kormos RL. Noninvasive assessment of myocardial recovery on chronic left ventricular assist device: Results associated with successful device removal. The Journal of heart and lung transplantation: The official publication of the International Society for Heart Transplantation. 2003;22:1304-13. (Pubitemid 37522033)
90. Simon MA, Kormos RL, Murali S, et al. Myocardial recovery using ventricular assist devices: Prevalence, clinical characteristics, and outcomes. Circulation. 2005;112:I32-6. (Pubitemid 41266650)
91. DandelM, Weng Y, Siniawski H, Potapov E, Lehmkuhl HB, Hetzer R. Long-term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices. Circulation. 2005;112:I37-45.
92. Lamarche Y, Kearns M, Josan K, et al. Successful weaning and explantation of the Heartmate II left ventricular assist device. Can J Cardiol. 2011;27:358-62.